Table 2. Predictors for early and late T2D remission after RYGB surgery for patients not using insulin (T2D) preoperatively.
Early remission (partial + complete) was defined by reaching diabetes-free status during the first two months after surgery. Late remission (partial + complete) was defined by reaching diabetes-free status more than two months after surgery. In univariate analysis for early T2D remission, there were 59 variables with p-value < 0·10 (35 with p-values < 0·05). In univariate analysis for late T2D remission, there were 54 variables with p-value < 0·10 (37 with p-values < 0·05). In both events, individual variables were added until the models below were developed. (% EWL: percent excess body weight loss).
| Early T2D remission
| ||||
|---|---|---|---|---|
| Odds ratio | 95% Confidence interval | p-value | ||
|
| ||||
| Age (years) | Each 10 year decrease | 1·41 | [1·10, 1·80] | 0·0071 |
|
| ||||
| Pre-operative HbA1c (%) | <6·5 | 11·53 | [4·32, 30·79] | <0·0001 |
| 6·5–6·9 | 6·27 | [2·21, 17·77] | 0·0006 | |
| 7·0–8·9 | 1·83 | [0·70, 4·83] | 0·220 | |
| 9·0+ | Reference | - | - | |
|
| ||||
| Pre-operative diabetes medications | Other* | 3·13 | [1·70, 5·75] | 0·0003 |
| ISA+Sulf‡ | Reference | - | - | |
|
| ||||
| Serum Insulin (μU/mL) | <17 | Reference | - | - |
| 17–30 | 1·13 | [0·64, 2·02] | 0·668 | |
| 30+ | 2·75 | [1·43, 5·28] | 0·0024 | |
|
| ||||
| Pre-operative use of leukotriene modifiers | Yes | 0·28 | [0·11, 0·70] | 0·0062 |
| No | Reference | - | - | |
|
| ||||
| Pre-operative LDL (mg/dL) | <125 | Reference | - | - |
| ≥125 | 2·26 | [1·17, 4·38] | 0·016 | |
|
| ||||
|
Late T2D remission
| ||||
| Hazard ratio | 95% Confidence interval | p-value | ||
|
| ||||
| Post-op % EWL | Each 10% increase | 1·31 | [1·18, 1·45] | <0·0001 |
|
| ||||
| Age (years) | Each 10 year decrease | 1·45 | [1·10, 1·92] | 0·0085 |
|
| ||||
| Pre-operative HbA1c (%) | <6·5 | 4·73 | [1·78, 12·59] | 0·0019 |
| 6·5–6·9 | 1·65 | [0·57, 4·79] | 0·359 | |
| 7·0–8·9 | 1·98 | [0·76, 5·18] | 0·165 | |
| 9·0+ | Reference | - | - | |
|
| ||||
| Pre-operative diabetes medications | Other* | 2·71 | [1·32, 5·56] | 0·0064 |
| ISA+Sulf‡ | Reference | - | - | |
|
| ||||
| Serum Insulin (μU/mL) | <17 | Reference | - | - |
| 17–30 | 1·77 | [0·96, 3·27] | 0·070 | |
| 30+ | 2·13 | [1·06, 4·29] | 0·035 | |
Other: none, Metformin (Met) only, Sulfonylurea (Sulf) only, insulin sensitizing agent other than metformin (ISA), Met+Sulf, Met+ISA.
ISA+Sulf: insulin sensitizing agent other than metformin + sulfonylurea therapy combined.